- Morphic Therapeutic, based in Waltham, Massachusetts, was acquired by Eli Lilly and Company for $3.2 billion.
- Odyssey Therapeutics, located in Boston, Massachusetts, secured $117.21 million in later-stage VC funding to further its oncology drug discovery platform. (Lead Investor: Ascenta Capital)
- HistoSonics, from Plymouth, Minnesota, raised $102 million in later-stage VC funding to develop its non-invasive robotic therapy platform. (Lead Investor: Alpha Wave Global)
- Linnaeus Therapeutics, based in Haddonfield, New Jersey, secured $1.63 million in later-stage VC funding to advance its oncology therapeutics.
- Cargo Therapeutics, located in San Carlos, California, raised $110 million through a PIPE deal to expand its oncology pipeline.
- Ikonisys, based in New Haven, Connecticut, raised $440,000 through a PIPE deal to develop its oncology diagnostics.
- Noetik, from San Francisco, California, raised $40 million in early-stage VC funding to innovate in AI-powered oncology diagnostics.
- Convergent Therapeutics, located in Cambridge, Massachusetts, secured $22.22 million in early-stage VC funding to advance its targeted radioisotope therapies.
- LinusBio, from North Brunswick, New Jersey, raised $6.15 million in early-stage VC funding to develop its precision oncology solutions.
- Talus Bio, based in Seattle, Washington, raised $9.42 million in seed funding to enhance its oncology drug discovery platform.
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.











